Target Validation Information | |||||
---|---|---|---|---|---|
Target ID | T99089 | ||||
Target Name | B-Raf proto-oncogene serine/threonine-protein kinase | ||||
Target Type | Successful |
||||
Drug Potency against Target | Sorafenib | Drug Info | Ki = 22 nM | [552459] | |
Vemurafenib | Drug Info | IC50 = 100 nM | [552844] | ||
References | |||||
Ref 552459 | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. | ||||
Ref 552844 | Inhibitors of c-jun-N-terminal kinase (JNK). Mini Rev Med Chem. 2008 Jul;8(8):755-66. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.